ITW — Illinois Tool Works Inc.

ITW's Q2 FY2026 report on 2026-07-28 beat consensus and management raised full-year EPS guidance to $11.35-11.55, initially lifting shares ~3.6%. But sentiment has since cooled: as of 2026-09-13 the stock is -8.32% over one month, -3.31% below its 20-day SMA and -4.25% below its 50-day, with RSI at 37.75. Analyst tone is genuinely split and leans cautious - 6 buy vs 13 hold and 9 sell, consensus 'Hold,' consensus target $280.71 - reflecting discomfort with a ~24x multiple for mid-single-digit organic growth rather than any deterioration in the actual numbers.

The trend is a clear, multi-quarter acceleration, not a blip. Revenue YoY growth stepped up from +2.3% (Q3 2025) to +4.1% (Q4 2025) to +4.6% (Q1 2026) to +6.1% (Q2 2026, $4.301bn vs $4.053bn). Operating margin has held a firm 26-27% band and expanded slightly YoY (Q2 2026 26.7% vs Q2 2025 26.3%), with Q3 2025 topping out at 27.4%. Diluted EPS grew +11.8% YoY in Q1 2026 ($2.66 vs $2.38) and +10.1% in Q2 2026 ($2.84 vs $2.58). One distortion worth flagging: Q3 2024 EPS of $3.91 versus $2.55 in Q3 2023 is an outlier (net income $1,160m exceeded operating income $1,052m, indicating a one-off tax/other benefit), so any YoY comparison spanning it is misleading. Free cash flow is solid and growing: TTM FCF through 2026-06-30 was $2.921bn versus $2.724bn a year earlier (+7.2%), with healthy quarterly conversion. This looks like an inflecting-up topline on a stable high-margin base.

Fair, leaning full - not cheap. As of 2026-09-13 the TTM P/E was 24.27x versus a 5-year average of 24.63x, so the stock trades right at its own historical norm, and P/S of 4.685x is likewise near the 5-year average of 4.76x. The PEG of -7.3 is noise (a negative number from a distorted trailing growth figure) and should be ignored. On forward earnings, ~23.4x FY2026 guidance midpoint EPS of $11.45x is a premium to the broad market, defensible by 24.5% ROIC and a 26.5% operating margin but not by growth alone. P/B of 26.5x and D/E of 3.35x look alarming but are largely artifacts of buyback-shrunken equity ($2.894bn), not distress. Verdict: fairly valued versus its own history, with no valuation cushion if growth slips.

The key tell as of 2026-09-13 is that estimates are going UP while the price goes DOWN - management raised FY2026 EPS guidance in late July, yet the stock fell 8.3% over the following month. That is multiple compression, not earnings skepticism: the market is de-rating a premium industrial rather than doubting the numbers. If Q3 (due 2026-10-23) confirms the guidance, the compressed multiple is an opportunity; if industrial demand rolls over, a 24x multiple on decelerating growth has real room to fall. Watch whether the stock can reclaim its 50-day SMA (~$280) - that would confirm the earnings story is winning over the rate/rotation story.

Weak short-term, intact long-term. As of 2026-09-13, RSI stood at 37.75 - approaching oversold but not there, so no capitulation signal yet. The stock sits -3.31% under its 20-day SMA and -4.25% under its 50-day SMA, but still +0.3% above its 200-day SMA, meaning the longer uptrend has not broken. One-week return was -0.73% and one-month -8.32%, against +4.17% over three months, so this is a sharp recent pullback within a range (52-week range $238.82-$303.16). Implication: not yet a technical buy; a decisive break below the 200-day (roughly $267) would be a real warning, while stabilization and a reclaim of ~$280 would mark a better entry.

• Elevated global interest rates keep a cautious capital-spending backdrop for heavy industrial customers, though ITW's low beta (0.997 per FMP) and pricing power cushion it relative to cyclical peers.
• Stark end-market divergence: weakness in North American and European Automotive OEM and Food Equipment versus strong structural demand in Welding (energy, infrastructure, aerospace/defense) and Test & Measurement/Electronics (semiconductor assembly).
• Input-cost timing and tariff pressure are an ongoing margin headwind that the 80/20 and enterprise initiatives (120bps of Q2 margin contribution) only partly offset.
• Sector rotation into and out of industrials based on rate-cut expectations - a big swing factor for a premium-multiple name like ITW.
• The semiconductor/electronics capital-expenditure cycle is a key swing variable, given Test & Measurement & Electronics is currently one of the strongest segments.

• Q3 FY2026 earnings on 2026-10-23 - the next major print; the question is whether electronics/welding momentum keeps offsetting soft auto OEM volumes and whether upwardly revised guidance is maintained.
• Ex-dividend in late September 2026 for the newly raised quarterly payout of $1.72/share (a 7% increase), plus execution on the new $6bn share repurchase program.
• Continued delivery of the enterprise initiatives / 80/20 process, which management targets for sustained margin expansion toward the 26.5-27.5% FY2026 range.
• Potential interest-rate cuts easing the industrial capex environment and supporting a re-rating of the multiple.
• Possible resolution of auto OEM and food equipment softness, which would broaden the recovery beyond the current electronics/welding strength.

• Premium valuation: ~24x TTM / ~23x forward leaves little cushion - the recent 8.3% one-month drop shows how fast the multiple can compress on sentiment alone.
• Cyclical end-market exposure in Automotive OEM and Food Equipment could deteriorate further if global industrial demand weakens.
• Leverage and thin equity: D/E 3.35, long-term debt $6.549bn against just $2.894bn of stockholders' equity and $839m cash - a balance sheet shaped by years of buybacks.
• Input-cost and tariff timing pressure could stall the margin expansion story that underpins the current multiple.
• Genuinely cautious sell-side skew (9 sell ratings versus only 6 buys) suggests limited near-term upside relative to consensus targets clustered near $280-296.

ITW is a genuinely high-quality compounder - 24.5% ROIC, 26.5% operating margin, 2.4% dividend yield, accelerating organic growth, and strong FCF - but it is trading at roughly its own 5-year average multiple, so there is no margin of safety. The recent 8% pullback after a guidance raise is multiple compression, not fundamental deterioration, which makes it interesting but not compelling. This is a solid long-term holding to accumulate on further weakness, not a name to chase at ~$268.

Blended forward-P/E method: FY2026 EPS of $11.45 (guidance midpoint, +9% YoY) growing ~5.7% to an FY2027 estimate of ~$12.10, multiplied by a justified 23.5x P/E - a slight discount to the 5-year average of 24.63x to reflect premium-valuation risk, the leveraged balance sheet (D/E 3.35), and mixed sell-side sentiment, but above the broad market given 24.5% ROIC and 26.5% operating margins. That yields 23.5 x $12.10 = $284.35, rounded to $284, essentially in line with where the stock trades, consistent with a fairly-valued high-quality name rather than a mispriced one.